Italian researchers have identified two new blood-based biomarkers that could improve early detection of pancreatic cancer, according to a study published in a recent medical journal.
The findings, reported by scientists in Italy, suggest that measuring levels of specific proteins in the blood may help identify pancreatic tumors at earlier, more treatable stages. Early diagnosis remains a major challenge in pancreatic cancer care, as the disease often presents no symptoms until it has advanced.
While the study does not yet confirm whether these biomarkers can be used in routine screening, researchers say the results represent a promising step toward developing non-invasive tools for earlier detection. Further validation in larger clinical trials will be needed before any potential clinical application.
The discovery highlights ongoing efforts to improve outcomes for one of the deadliest forms of cancer, where survival rates remain low largely due to late-stage diagnosis. Any advancement in early detection could significantly impact patient prognosis and treatment options.
